Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
Article By Greg Cima / April 25, 2023
Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
Outcome Capital Named Top Life Sceneces Investement Banking Firm 2025 by Life Science Review January 2025 Read the full article from Life Science Magazine here: Read More
Read MoreOutcome Capital Life Science Market Pulse December 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?